65 results about "Intravenous IG" patented technology

The use of classical superantigens for treatment of cancer has resulted in a low response rates and serious toxicity in humans which is attributable, in part, to the presence of preformed superantigen specific antibodies in the plasma of treated patients. The present invention addresses this problem by providing a method for treating tumors comprising the administration of one or a plurality of egc (enterotoxin gene cluster) staphylococcal enterotoxins comprising staphylococcal enterotoxins G, I, M, N, O. These superantigens in native unmodified form can be administered intrathecally, intratumorally, intravenously to humans with advanced lung cancer while resolving pleural effusions and prolonging survival to 300% above control patients treated with talc pleurodesis. Intratumoral egc superantigens induces a significant and sustained reduction of the tumor size. In contrast to classic Sags, the egc superantigens induced minimal toxicity, are rarely associated with the presence of preformed antibodies and are used as a plurality with a broad T cell Vβ profile. Useful egc superantigen compositions for parenteral administration native egc enterotoxins, homologues, fragments and fusion proteins of native egc enterotoxins capable of activating a broad spectrum of T cells expressing T cell receptor/α motifs. T cell survival-enhancing cytokines IL-7, Il-15, Il-23 are used. together with parenteral egc SE therapy. Also disclosed is combined therapy that includes parenteral, intratumoral or intrathecal superantigen compositions in combination with (i) intratumoral low, non-toxic doses of one or more chemotherapeutic drugs or (ii) systemic chemotherapy at reduced and non-toxic doses of chemotherapeutic drugs or (iii) radiation therapy or (iv) anti-angiogenic and tyrosine kinase inhibitors.

The present invention relates to the use of MRI monitoring of ventricular enlargement rate as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen for Alzheimer's patients. Methods for treating Alzheimer's Disease and monitoring therapeutic effectiveness are provided.

The invention relates to a functionalized arborescent macro radical carrier system for targeting malignant cerebroma. The functionalized arborescent macro radical carrier system is obtained by taking one or more of the following combinations as the targeting functional factor: transferrin and transferrin monoclonal antibody, or polyclonal antibody, folic acid (FA) and epidermal growth factor receptor monoclonal antibody, or polyclonal antibody and RGD cyclic peptide, chemically connecting the combinations to arborescent macro radical polyamide-amine (PAMAM) carrier system, and then compounding the combinations with treatment factor oligonucleotide, siRNA molecule or plasmid DNA. Through intra-tumor stereotactic injection, carotid injection or tail vein, the distribution of genes in the malignant cerebroma can be improved, high expression can be realized, and the effective cerebroma inhibition can be realized. Compared with the commercialized gene carrier Oligofectamin and unmodified PAMAM, the FA-PAMAM can remarkably improve the targeting delivery ability of the in vitro and in vivo genes.

The invention is a method of treatment of the symptoms related to inflammation that accompanies the release of Tumor Necrosis Factor-alpha in diseases such as viral infection such as those affecting the respiratory tract by providing systemic glutathione (reduced) by oral administration of glutathione (reduced) in a liposome encapsulation or by the intravenous administration of reduced glutathione. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms of disease induced by the release of TNF-α in infectious disease states such as respiratory and other viruses. The product is novel in that it is stable across the temperature ranges encountered in shipping and does not need to be refrigerated for storage. Compounds enhancing the effect of the liposomal glutathione as well as intravenous glutathione are contemplated such as Selenium.

The invention discloses a new use of T-2 toxin, that is, application of T-2 toxin in the preparation of drugs for treating bone cancers and myeloproliferative disorder, wherein the curative dose thereof is 0.1-20 mg/Kg (weight), preferably 0.5-8 mg/Kg (weight), during drug administration, the method comprises oral administration, intravenous injection, hypodermic injection and intramuscular injection. The invention establishes animal or cell models of multiple myeloma, osteosarcoma and myelodysplastic syndrome, and inspects the inhibition of the T-2 toxin on the tumors or tumor cells by injection or cell co-culture. The experiment shows that the T-2 toxin is capable of inhibiting the growth of tumor cells and has good killing effect on the bone cancers and myeloproliferative disorder.

The present invention relates to the use of the level of certain cytokines in a patient's blood as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiveness of a treatment regimen. Methods for treating Alzheimer's disease and monitoring therapeutic effectiveness are provided.

The invention discloses a method for detecting an activated blood coagulation factor XI in human intravenous immunoglobulin. The method comprises the steps as follows: (1) mixing an IVIG (intravenous immunoglobulin) sample with specially-preprocessed platelet-poor plasma (PPP); (2) adding a thrombin specific fluorogenic substrate with a phospholipid agent into a reaction system; (3) adding an initiation factor for starting a TGT (thrombin generation test), wherein the initiation factor comprises a calcium ion source and the phospholipid agent; (4) obtaining a thrombin generation curve providing parameters by the optimized reaction system; and (5) negatively correlating the peak time of thrombin (TTP) of the detected sample with the FXIa (activated blood coagulation factor XI) level in the sample. The FXIa level in the detected sample can be indirectly obtained by comparing the TTP of the detected sample with that of an FXIa standard sample. The method is suitable for detecting residual micro FXIa in human intravenous immunoglobulin (IVIG) products and is used for extracorporal evaluation of thrombosis risk of related products.

The invention relates to a method for preparing immunoglobulin G by rapidly extracting plasma of a COVID-19 patient in a rehabilitation period, and more particularly, to a method for preparing intravenous injection COVIDI-19 immunoglobulin G by rapidly separating component plasma from whole blood by using a closed multicellular component automatic separation system (MACSS), for example, to prepareintravenous injection superimmunoglobulin. The intravenous immunoglobulin can be used for treating patients infected by novel coronavirus. The method comprises the following steps: separating human peripheral blood into three component layers, namely an erythrocyte layer, a cell concentration layer and a plasma layer, by using a closed multi-cell component automatic separation system, and then carrying out virus inactivation on the obtained plasma to obtain plasma capable of being used for preparing intravenous immunoglobulin G. The invention also relates to a method for preparing an intravenous immunoglobulin G preparation by using the plasma component obtained by the above method. According to the method, the plasma obtaining speed is high, and the antibody titer of the prepared plasmaand intravenous immunoglobulin G is high.

The invention relates to the field of biopharmaceutics, in particular to a liposome preparation for anticoagulant thrombolytic difunctional fusion protein, namely anticoagulant thrombolytic difunctional fusion protein of 12 peptides of hirudin and reteplase (HV12p-rPA) and a preparation method thereof. The anticoagulant thrombolytic difunctional fusion protein (HV12p-rPA) constructed in the laboratory has the dual effects of anticoagulation and thrombolysis by structural identification, expression, chromatography renaturation, purification and extracorporal and intracorporal pharmacodynamic experiments. In the preparation method, the liposome preparation is prepared from the anticoagulant thrombolytic difunctional fusion protein serving as a raw material, and a liposome is prepared by an optimized membrane dispersion-probe ultrasonic method; and the optimized membrane dispersion-probe ultrasonic method is characterized in that a prescription which is most suitable for improving the envelop rate of the HV12p-rPA liposome is selected by taking a ratio of phospholipid to cholesterol, the concentration of protein medicaments, the volume of buffer solution and water-bath ultrasonic time as influence factors, and the grain diameter of the HV12p-rPA liposome is reduced and homogenized further by probe ultrasonic, so that the HV12p-rPA liposome of which the grain diameter is between 140 and 145 nanometers and which is used for intravenous injection is prepared. By the preparation method, the envelop rate of the prepared HV12p-rPA liposome is over 90 percent, and extracorporal thrombolytic activity and extracorporal anticoagulant activity are 23,810 international unit (IU) .mg<1> and 414 antithrombin unit (ATU) .mg<1> respectively.

The invention discloses a non-viral vector, and a preparation method and application thereof. The non-viral vector is nanoparticles prepared by blending polyethyleneimine and a compound shown in a formula V. A vector of a medicament provided by the invention is the non-viral vector provided by the invention. The medicament comprises the non-viral vector provided by the invention and a therapeuticDNA wrapped in the non-viral vector. The target tumor of the medicament is highly expressed by a folate receptor FRalpha. The tumor which can be targeted by the medicament is a folate receptor FRalpha negatively-expressed tumor and heart. After being intravenously injected into a tumor-bearing mouse inoculated with the tumor of folate receptor positive cells, the non-viral vector provided by the invention can carry gene specificity to the tumor cells and continuously and effectively express target genes in the tumor cells.

To identify novel agents to treat carbapenem-resistant Acinetobacter baumannii. the Inventors used a nutrient-depleted medium with serum to mimic the in vivo environment. In RPMI with serum, the screen identified rifabutin (RBT) as being 133-fold more potent than rifampin (RIF) against A. baumannii, with MICs of 0.031 μg/ml and 4 μg/ml respectively. No difference in RBT vs. RIF activity was observed when MHII was used as the culture media. RBT possesses markedly superior in efficacy to RIF in murine models of lethal iv and pneumonia models of infection with a hyper-virulent, clinical lung and blood isolate of extreme-drug resistant (XDR) A. baumannii. In both models, RBT significantly improved survival and lowered bacterial burden compared to RIF. RBT is a promising, novel therapeutic option for A. baumannii infections.

An acid-modified arabinogalactan protein composition, having an arabinose-galactose ratio of less than 3.5:1 or less than 80% of the arabinose:galactose ratio of the arabinogalactan protein component of the composition prior to acid modification, prepared from Astragalus membranaceus, especially from the roots of Atragalus membranaceus, is capable of reconstitution into an aqueous intravenously injectable formulation; and is useful for stimulating hematopoiesis, inducing the proliferation or maturation of megakaryocytes, stimulating the production of IL-1beta, Il-6, TNF-alpha, IFN-gamma, GM-CSF, or G-CSF, stimulating the production or action of neutrophils, treating neutropenia, anemia, or thrombocytopenia, accelerating recovery from exposure (e.g. accidental or non-therapeutic exposure, as well as therapeutic exposure) to cytotoxic agents or radiation, treating cachexia, emesis, or drug withdrawal symptoms, or modifying biological responses or protecting hepatic cells in hepatitis B, in a mammal when intravenously administered to the mammal.

This provides pharmaceutical compositions that comprise (i) an anti-LAG-3 antibody or antigen binding fragment thereof or (ii) an anti-LAG-3 antibody or antigen binding fragment thereof and an anti-PD-1 antibody, anti-PD-L1 antibody, or antigen binding fragment thereof. Also provided are pharmaceutical compositions that comprise a buffering agent, stabilizing or bulking agent, and a surfactant. The disclosure also provides a vial, syringe, intravenous bag, or kit that comprises the compositions, and methods for using the compositions.

A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general vascular therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents and spasm inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. Specific preferred embodiments of the solution of the present invention for use in cardiovascular and general vascular procedures also include anti-restenosis agents. The solution is introduced luminally to continuously irrigate an arterial site during an operative/interventional or diagnostic procedure for preemptive inhibition of pain and inflammation, vascular and non-vascular smooth muscle spasm, and restenosis while avoiding undesirable side effects associated with oral, intramuscular, subcutaneous or intravenous application of larger doses of the agents. One preferred solution to inhibit pain, inflammation, vasospasm and restenosis includes a serotonin2 antagonist, a cyclooxygenase inhibitor, an endothelin antagonist, an ATP-sensitive K<+> channel antagonist, a Ca<2+> channel antagonist, a nitric oxide donor, an anti-thrombin agent, a glycoprotein IIb/IIIa receptor blocker, a PKC inhibitor and a protein tyrosine kinase inhibitor.

The invention discloses a use of neutrophil gelatinase-associated lipocalin in promoting a therapeutic antibody to cross a blood-brain barrier. The therapeutic antibody is a nanocapsule containing immune globulin. The neutrophil gelatinase-associated lipocalin enters blood through intravenous injection to play a role in increasing the permeability of a blood-brain barrier. According to the presentinvention, lipoprotein related to neutrophil gelatinase is intravenously injected into blood circulation of a glioma animal model, the permeability of a blood-brain barrier can be improved, and therefore the total amount of therapeutic antibodies crossing the blood-brain barrier is increased, and particularly, when the therapeutic antibodies select nanocapsules containing immune globulin, the effect that the medicine passes through the blood-brain barrier can be further improved, a better treatment effect is achieved, and extremely high clinical transformation significance is achieved.

The invention relates to a method for rapidly extracting plasma of a COVED-19 patient in a rehabilitation period by an automatic separation system. The method comprises the following steps of: separating peripheral blood taken from a human body into three component layers, namely an erythrocyte layer, a cell concentration layer and a plasma layer, by using a closed multi-cell component automatic separation system, performing virus inactivation on the obtained plasma, and optionally cryopreserving the plasma to obtain the plasma which can be used for preparing intravenous immunoglobulin G. Theinvention also comprises a method for preparing an intravenous immunoglobulin G preparation. The method comprises the following steps: obtaining a plasma component by the method, precipitating the plasma by a low-temperature ethanol method to obtain components I + II + III, separating a component II from a component I + III, respectively preparing an immunoglobulin G semi-finished product 1 and animmunoglobulin G semi-finished product 2, performing sterilization and virus inactivation to obtain an immunoglobulin G stock solution. and further preparing the intravenous immunoglobulin G preparation for intravenous injection. The method provided by the invention achieves excellent technical effects as described in the specification.

The invention discloses a method for creating an autoimmune hepatitis animal model, which comprises the following steps: (1) injecting CCl4 into the abdominal cavity of a mouse on the d0 day once every 7 days, and stopping injecting CCl4 on the fourteenth day; (2) intravenously injecting plasmids CYP2D6 into the tail of the mouse for the first time 2 days before CCl4 injection, then injecting the plasmids CYP2D6 once every 7 days, and stopping injecting the plasmids CYP2D6 until the d54 day; and (3) respectively detecting liver inflammation, liver injury, autoantibody production and cytokine expression of the mouse on d30 days, d40 days, d50 days and d60 days, comparing the results of the liver inflammation, the liver injury, the autoantibody production and the cytokine expression with those of a normal mouse, taking the results as contrasts at different time points, comparing, and as time goes on, determining that the results of the liver inflammation, the liver injury, the autoantibody production and the cytokine expression are different. And if the detected indexes become more and more obvious, the modeling is successful.

The invention relates to a mumps virus attacking animal model and an establishment method thereof, and belongs to the technical field of biology. The invention provides a mumps virus counteracting animal model. The mumps virus counteracting animal model is an interferon receptor deletion animal which is intravenously injected with mumps virus. Research finds that compared with common mice, the mumps virus load in blood of the interferon receptor-deleted mice is remarkably improved after the mumps virus is attacked by the interferon receptor-deleted mice, and compared with intramuscular injection and intranasal injection, the mumps virus load in blood of the interferon receptor-deleted mice is remarkably improved after the mumps virus is injected into the interferon receptor-deleted mice through caudal veins, so that the mumps virus load in blood of the interferon receptor-deleted mice is remarkably improved. Intravenous injection of the mumps virus to the interferon receptor-deficient animal can break through species limitation, effective infection of the mumps virus in the animal body is realized, and symptoms similar to human infection (for example, remarkable replication in various visceral organs) are formed, so that the mumps virus challenge animal model can be used as the mumps virus challenge animal model.

The invention provides a reagent for predicting treatment reactivity of children with Kawasaki disease and an application of the reagent, and mainly provides the reagent for detecting an intravenous human immunoglobulin (IVIG) non-responsive Kawasaki disease susceptibility gene and a kit containing the reagent. The reagent can evaluate the reactivity of the children with the Kawasaki disease to IVIG treatment by detecting 5 SNP loci of 3 genes (rs10056474 or rs746994 of an SMAD5 gene, rs76863441 of a PLA2G7 gene, and/or rs16944 or rs1143627 of an IL-1B gene) of a patient. The kit has the characteristics of simple operation and low costs; and the reagent and kit provided by the invention can provide a basis for screening IVIG non-responsive high-risk children as early as possible and guiding clinical doctors to take reasonable intervention and treatment measures, and is in line with the development trend of precision medicine.